for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)
Ceftolozane/tazobactam, which is being developed as a first-line intravenous therapy for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, advanced into Phase 3 trials in July 2011…
Lexington, Mass., June 13, 2013 – Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Dr. Lorianne Masuoka to Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs.
A Clinical Business Manager in the Birmingham West region, Keith sees himself as one of the “faces of Cubist” with the…
View our Careers page to see all current opportunities with Cubist.
